-
21.发明申请Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof 审中-公开少突胶质细胞 - 髓磷脂糖蛋白组合物及其使用方法公开(公告)号：US20090175846A1
公开(公告)日：2009-07-09
申请号：US12091564
申请日：2006-10-27
申请人： Sha Mi , R. Blake Pepinsky
发明人： Sha Mi , R. Blake Pepinsky
IPC分类号： A61K39/395 , C12N5/06 , A61K31/7088 , A61K38/02 , A61K35/12
CPC分类号： A61K38/17 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0356 , C07K14/70503 , C12N15/8509
摘要： The present invention is based on the discovery that oligodendrocyte-myelin glycoprotein (OMgp), which is ex-pressed by oligodendrocytes and CNS myelin, negatively regulates oligodendrocyte and neuronal differentiation and survival. Based on these discoveries, the invention relates generally to methods of promoting neuronal and oligodendrocyte survival and differentiation by administration of an OMgp anatagonist. Additionally, the invention generally relates to methods of treating various diseases, disorders or injuries associated with demyelination, dysmyelination, oligodendrocyte/neuronal cell death, axonal injury and/or differentiation by the administration of an OMgp antagonist.
摘要翻译： 本发明是基于由少突胶质细胞和CNS髓鞘表达的少突胶质细胞 - 髓磷脂糖蛋白（OMgp）负调节少突胶质细胞和神经元分化和存活的发现。 基于这些发现，本发明一般涉及通过施用OMGP拮抗剂来促进神经元和少突胶质细胞存活和分化的方法。 此外，本发明一般涉及治疗与脱髓鞘相关的各种疾病，病症或损伤，通过施用OMgp拮抗剂的脱髓鞘，少突胶质细胞/神经元细胞死亡，轴索损伤和/或分化的方法。
-
公开(公告)号：US20130096065A1
公开(公告)日：2013-04-18
申请号：US13541302
申请日：2012-07-03
CPC分类号： C07K14/495 , A61K38/00 , A61K38/185 , A61K47/60 , C07K14/47 , C07K14/4756 , C07K19/00
摘要： Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal.
摘要翻译： 公开了在所选择的氨基酸残基处具有取代的变体Neburgastin多肽。 在一个或多个选择的氨基酸残基上的取代降低了肝素结合并增加了变异体恩波斯汀多肽的血清暴露。 还公开了使用变体Neburgastin多肽治疗哺乳动物的病症并激活RET受体的方法。
-
公开(公告)号：US08263553B2
公开(公告)日：2012-09-11
申请号：US11573773
申请日：2005-08-18
CPC分类号： C07K14/495 , A61K38/00 , A61K38/185 , A61K47/60 , C07K14/47 , C07K14/4756 , C07K19/00 , Y02A50/473
摘要： Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
摘要翻译： 公开了在所选择的氨基酸残基处具有取代的变体Neburgastin多肽。 在一个或多个选择的氨基酸残基上的取代降低了肝素结合并增加了变异体恩波斯汀多肽的血清暴露。 还公开了使用变体Neburgastin多肽治疗哺乳动物的病症并激活RET受体的方法。
-
24.发明申请公开(公告)号：US20090062199A1
公开(公告)日：2009-03-05
申请号：US12064753
申请日：2006-08-25
申请人： Dingyi Wen , Daniel H.S. Lee , R. Blake Pepinsky
发明人： Dingyi Wen , Daniel H.S. Lee , R. Blake Pepinsky
CPC分类号： C07K14/705
摘要： Nogo receptor 1 (NgR1) is a leucine rich repeat protein that forms part of a signaling complex that modulates axon regeneration. Previous studies have shown that the entire LRR region of Nogo receptor-1, including the C-terminal cap of LRR, LRRCT, is needed for ligand binding, and that the adjacent CT stalk of the Nogo receptor-1 contributes to interaction with its co-receptors. The present invention is directed to the use of certain Nogo receptor-1 and Nogo receptor-2 polypeptides and polypeptide fragments for promoting neurite outgrowth, neuronal survival, and axonal regeneration in CNS neurons. The invention features molecules and methods useful for inhibiting neurite outgrowth inhibition, promoting neuronal survival, and/or promoting axonal regeneration in CNS neurons.
摘要翻译： Nogo受体1（NgR1）是富含亮氨酸的重复蛋白，其形成调节轴突再生的信号复合物的一部分。 以前的研究表明，配体结合需要Nogo受体-1的整个LRR区域，包括LRR的C端帽，LRRCT，Nogo受体-1的相邻CT茎与其co 接受者 本发明涉及某些Nogo受体-1和Nogo受体-2多肽和多肽片段在CNS神经元中促进神经突生长，神经元存活和轴突再生的用途。 本发明的特征在于可用于抑制神经突增生抑制，促进神经元存活和/或促进CNS神经元中的轴突再生的分子和方法。
-
公开(公告)号：US20080306212A1
公开(公告)日：2008-12-11
申请号：US12163425
申请日：2008-06-27
申请人： Dinah Wen-Yee Sah , R. Blake Pepinsky , Paula Ann Boriack-Sjodin , Stephan S. Miller , Anthony Rossomando , Laura Silvian
发明人： Dinah Wen-Yee Sah , R. Blake Pepinsky , Paula Ann Boriack-Sjodin , Stephan S. Miller , Anthony Rossomando , Laura Silvian
IPC分类号： C08G63/91
CPC分类号： C07K14/475 , A61K38/00 , A61K39/00 , A61K47/60 , C07K14/4756 , C07K2319/00
摘要： A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.
摘要翻译： 公开了包含与聚合物偶联的突变的新伯斯加蛋白多肽的二聚体。 这种二聚体表现出延长的生物利用度，并且在优选的实施方案中，相对于野生型形式的新霉素具有延长的生物活性。
-
公开(公告)号：US5747641A
公开(公告)日：1998-05-05
申请号：US451233
申请日：1995-05-25
IPC分类号： A61K38/00 , A61K39/00 , A61K47/48 , A61K49/00 , C07K14/025 , C07K14/16 , C07K14/21 , C07K14/47 , C12N9/08 , C12N9/22 , C12N15/62 , C12N15/87 , C07K2/00 , C07K14/00 , C07K14/155
CPC分类号： C12Y111/01007 , A61K47/48238 , A61K49/00 , C07K14/005 , C07K14/21 , C07K14/47 , C12N15/62 , C12N15/87 , C12N9/0065 , C12N9/22 , A61K2123/00 , A61K38/00 , A61K39/00 , C07K2319/00 , C07K2319/10 , C07K2319/55 , C07K2319/71 , C07K2319/80 , C12N2710/20022 , C12N2740/16322
摘要： This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation. The reduced size of the preferred transport polypeptides of this invention also minimizes interference with the biological activity of the cargo molecule.
摘要翻译： 本发明涉及生物活性物质分子如多肽和核酸在体外和体内递送到细胞的细胞质和细胞核中。 根据本发明的货物分子的细胞内递送通过使用包含HIV tat蛋白或其一个或多个部分并且共价连接到货物分子的新型转运多肽来实现。 本发明优选实施方案中的转运多肽的特征在于存在tat碱基区（氨基酸49-57），缺少富含半胱氨酸的区域（氨基酸22-36）和不存在tat外显子 2编码的天然存在的tat蛋白的羧基末端结构域（氨基酸73-86）。 由于缺乏富含半胱氨酸的区域，本发明优选的转运多肽解决了假反式激活和二硫键聚集的潜在问题。 本发明优选的转运多肽的减小的尺寸还使对货物分子的生物活性的干扰最小化。
-
27.发明授权DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides 失效DNA序列，重组DNA分子和产生脂质素样多肽的方法
公开(公告)号：US5081019A
公开(公告)日：1992-01-14
申请号：US519256
申请日：1990-05-02
CPC分类号： C07K14/4721 , C12N15/72 , C12N15/81 , C12N15/85 , A61K38/00
摘要： DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human lipocortin-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human lipocortin-like polypeptide. In appropriate hosts these DNA sequences permit the production of human lipocortin-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.
摘要翻译： DNA序列，重组DNA分子和用它们转化的宿主产生人脂多糖样多肽，以及制备和使用这些产物的方法。 DNA序列和重组DNA分子的特征在于它们编码人类脂质皮质素样多肽的表达。 在合适的宿主中，这些DNA序列允许生成用作抗炎剂的人类脂质皮质素样多肽，以及用于治疗关节炎，过敏，皮肤病学，眼科和胶原疾病以及涉及炎症过程的其它病症的方法。
-
公开(公告)号：US09005926B2
公开(公告)日：2015-04-14
申请号：US13499858
申请日：2010-10-01
IPC分类号： C07K1/04 , C07K1/113 , C07K16/00 , C07K1/26 , G01N30/02 , G01N33/534 , G01N33/563
CPC分类号： C07K16/00 , C07K1/1133
摘要： The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
摘要翻译： 本发明涉及在蛋白质如抗体中预防和消除三硫键的方法。 在一个实施方案中，作为色谱纯化方法的一部分，将蛋白质中的三硫键转化为二硫键。 在另一个实施方案中，通过在这些蛋白质的细胞培养生产期间实施本文所述的方法来抑制蛋白质中三硫键的形成。 在另一个实施方案中，通过本文所述的方法产生单克隆抗体。
-
公开(公告)号：US08642732B2
公开(公告)日：2014-02-04
申请号：US13425583
申请日：2012-03-21
CPC分类号： C07K14/4756 , A61K38/00
摘要： The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.
摘要翻译： 公开了以下类别的分子：含有第一新斯普鲁斯丁蛋白多肽和第二新伯斯加蛋白多肽的二聚体，其中：（a）至少一种多肽被糖基化; （b）至少一种多肽在其N-末端与水溶性合成聚合物共轭; 和（c）在N-末端以外的位置，任何一种多肽都不与水溶性合成聚合物共轭。 这种二聚体具有野生型新伯斯汀的生物活性，同时显示相对于野生型新霉素的增强的血清半衰期和增强的效力。
-
公开(公告)号：US20120014916A1
公开(公告)日：2012-01-19
申请号：US13230080
申请日：2011-09-12
申请人： KoChung Lin , R. Blake Pepinsky , Ling Ling Chen , Donna M. Hess , Edward Y. Lin , Russell C. Petter , Darren P. Baker
发明人： KoChung Lin , R. Blake Pepinsky , Ling Ling Chen , Donna M. Hess , Edward Y. Lin , Russell C. Petter , Darren P. Baker
CPC分类号： C08G65/329 , A61K47/60 , C08L2203/02
摘要： The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.
摘要翻译： 本发明涉及新型聚亚烷基二醇化合物及其使用方法。 特别地，包含新型聚乙二醇缀合物的化合物单独使用或与抗病毒剂组合用于治疗病毒感染，例如慢性丙型肝炎。
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.034 秒)